Disentangling the Cost of Orphan Drugs Marketed in the United States

The increasing number and high prices of orphan drugs have triggered concern among patients, payers, and policymakers about the affordability of new drugs approved using the incentives set by the Orphan Drug Act (ODA) of 1983. This study evaluated the factors associated to the differences in the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Althobaiti, Hana, Seoane-Vazquez, Enrique, Brown, Lawrence M., Fleming, Marc L., Rodriguez-Monguio, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957503/
https://www.ncbi.nlm.nih.gov/pubmed/36833091
http://dx.doi.org/10.3390/healthcare11040558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957503/
https://www.ncbi.nlm.nih.gov/pubmed/36833091
http://dx.doi.org/10.3390/healthcare11040558

Ejemplares similares